Live Breaking News & Updates on பீட்டர் லெவெலின் டேவிஸ்

Stay updated with breaking news from பீட்டர் லெவெலின் டேவிஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

APEIRON Biologics Announces Changes to Management and Supervisory Boards

APEIRON Biologics Announces Changes to Management and Supervisory Boards
DGAP-News: APEIRON Biologics AG
/ Key word(s): Personnel
01.06.2021 / 10:00
APEIRON Biologics Announces Changes to Management and Supervisory Boards
Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO)
Prof. Josef Penninger moves from the Supervisory Board to the newly created Scientific Advisory Board, which he will build up and lead as Chairman
APEIRON to propose Ulrich Granzer PhD as new member of the Supervisory Board at the upcoming Annual General Meeting
Vienna, Austria, 1 June 2021: APEIRON Biologics AG, a privately held biotechnology company developing novel immunotherapies for cancer and respiratory diseases, today announced changes to the Company s Management and Supervisory Boards. ....

Andreas Gerber , Merck Sharpe Dohme , Andreas Jungfer , Edward Charles , Rainer Burian , Julia Hofmann , Josef Penninger , Ulrich Granzer , Manfred Reichl , Romana Gugenberger , Fed Charles , Pharma Knoll , Peter Llewellyn Davies , Pharma Ltd , Mc Services , Bayer Ag , University Of St , Company Management , University Of Basel , Distribution Services , Company Supervisory Board , Granzer Regulatory Consulting Services , Research Development Department , Head Of Research Development , University Of Vienna , Announces Changes ,

APEIRON Biologics' APN01 selected for large-scale US trial in COVID-19

APEIRON Biologics APN01 selected for large-scale US trial in COVID-19
DGAP-News: APEIRON Biologics AG
/ Key word(s): Study
19.05.2021 / 09:00
APEIRON Biologics APN01 selected for large-scale US trial
in COVID-19
APEIRON s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS
Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue
Additional pre-clinical data show highly promising results with APN01 in various mutation variants
Financing round planned to secure funding of further upcoming development steps
Vienna, Austria, 19 May 2021: APEIRON Biologics AG announced today the next development steps for APN01 (alunacedase alfa) for the treatment of COVID-19. Based on the recently announced clinical results from APEIRON s Phase 2 trial with APN01 in COVID-19, APN01 will be developed in further international clinical trials with different COVID-19 patient ....

United Kingdom , South Africa , South African , Julia Hofmann , Romana Gugenberger , Sean Collins , Peter Llewellyn Davies , Andreas Jungfer , Pharma Ltd , Mc Services , Collaborative Network Of Networks , Vanderbilt Institute For Clinical , National Heart Lung , United State National Institutes Of Health , Emergency Medicine At Vanderbilt University Medical Center , Translational Research , Blood Institute , United State National Institutes , Collaborative Network , Renin Angiotensin Aldosterone System , Chief Executive Officer , Emergency Medicine , Vanderbilt University Medical Center , Chronic Obstructive Pulmonary Disease , Pulmonary Arterial Hypertension , Vanderbilt Institute ,

APEIRON Biologics AG: APEIRON Biologics' APN01 Selected for Large-Scale US Trial in COVID-19

APEIRON Biologics AG: APEIRON Biologics APN01 Selected for Large-Scale US Trial in COVID-19
APEIRON s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS
Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue
Additional pre-clinical data show highly promising results with APN01 in various mutation variants
Financing round planned to secure funding of further upcoming development steps
VIENNA, AUSTRIA / ACCESSWIRE / May 19, 2021 / APEIRON Biologics AG announced today the next development steps for APN01 (alunacedase alfa) for the treatment of COVID-19. Based on the recently announced clinical results from APEIRON s Phase 2 trial with APN01 in COVID-19, APN01 will be developed in further international clinical trials with different COVID-19 patient populations and drug delivery routes. ....

United Kingdom , South Africa , South African , Julia Hofmann , Kostenloser Wertpapierhandel , Romana Gugenberger , Sean Collins , Peter Llewellyn Davies , Andreas Jungfer , Pharma Ltd , Mc Services , Collaborative Network Of Networks , Vanderbilt Institute For Clinical , National Heart Lung , United State National Institutes Of Health , Emergency Medicine At Vanderbilt University Medical Center , Translational Research , Blood Institute , United State National Institutes , Collaborative Network , Renin Angiotensin Aldosterone System , Chief Executive Officer , Emergency Medicine , Vanderbilt University Medical Center , Chronic Obstructive Pulmonary Disease , Pulmonary Arterial Hypertension ,

Apeiron-Chef: "Regierung muss uns mehr unter die Arme greifen"

Apeiron-Chef: "Regierung muss uns mehr unter die Arme greifen"
kurier.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kurier.at Daily Mail and Mail on Sunday newspapers.

United States , Josef Penninger , Christoph Huber , Peter Llewellyn Davies , Software Inc , Companies Such As Biontech Or , Your Target Group , Fund For The , Josef Penninger Founded Vienna Biotech Schmiede , Ceo Peter Llewellyn Davies , There Are , Not Have , Target Group , Covid Erkrankung Are , Money Is Intended , Apeiron Medikament Apn , Money Came , Also Participate , State High , More Innovation , Have Invested , First Place , Agree With , Central Shopping At The , Would Also , Which In Turn Is Dependent ,

Covid-Medikament von Wiener Firma mit positiven Studiendaten | Tiroler Tageszeitung Online

Covid-Medikament von Wiener Firma mit positiven Studiendaten | Tiroler Tageszeitung Online
tt.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tt.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Josef Penninger , Alunacedase Alpha , Peter Llewellyn Davies , University Of British Colombia , Team Has Beena Tendency , Development Of Apn , Tyrolean Newspaper , Denmark Eurussia Carried , Patients Were , Medical Complications , Care And , These Results , Steam Has Been , Yoga Set , Win The , British Colombia , Detailed Analysis , ஒன்றுபட்டது கிஂக்டம் , பீட்டர் லெவெலின் டேவிஸ் , பல்கலைக்கழகம் ஆஃப் பிரிட்டிஷ் கொலம்பியா , நோயாளிகள் இருந்தன , பராமரிப்பு மற்றும் , வெற்றி தி , பிரிட்டிஷ் கொலம்பியா , விரிவானது பகுப்பாய்வு ,